Get the Stockscreener App
52.34
0.87%
0.45
Pre-market:
52.40
0.06
+0.11%
Kiniksa Pharmaceuticals International Plc stock is traded at $52.34, with a volume of 627.22K.
It is up +0.87% in the last 24 hours and down -7.38% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
See More
Previous Close:
$51.89
Open:
$51.75
24h Volume:
627.22K
Relative Volume:
0.94
Market Cap:
$4.03B
Revenue:
$754.05M
Net Income/Loss:
$73.06M
P/E Ratio:
57.69
EPS:
0.9073
Net Cash Flow:
$164.23M
1W Performance:
+6.73%
1M Performance:
-7.38%
6M Performance:
+25.97%
1Y Performance:
+84.95%
1-Day Range:
$51.70
$53.27
1-Week Range:
$48.48
$53.27
52-Week Range:
$26.27
$59.87
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
52.34 | 4.03B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Canaccord Genuity | Buy |
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Spruce Street Capital LP Purchases New Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Q1 2026 Earnings: EPS Surpasses Estimates by Over 31%Earnings Growth Analysis - newsline.com
Castleark Management LLC Raises Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA: Record ARCALYST growth, robust pipeline, and key clinical catalysts drive future momentum - TradingView
Kiniksa Pharmaceuticals (KNSA) Edges Lower, Testing Key Support LevelsZero Gamma Level - newsline.com
ESSEX INVESTMENT MANAGEMENT CO LLC's Kiniksa Pharmaceuticals International PLC(KNSA) Holding History - GuruFocus
KNSA Q1 2026 Earnings: EPS Surges Past Estimates, Stock Gains 2.88%Analyst Earnings Estimate - newsline.com
219,591-share cashless exercise reported by Kiniksa (NASDAQ: KNSA) - Stock Titan
BNP Paribas Financial Markets Has $34.31 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa (KNSA) director receives RSUs and options in equity grants - Stock Titan
Kiniksa (KNSA) director Popovits exercises 2,799 RSUs and receives 12,158-share option grant - Stock Titan
CEO-linked trust converts 900,000 Kiniksa (NASDAQ: KNSA) Class B shares - Stock Titan
Kiniksa (NASDAQ: KNSA) director exercises 2,799 RSUs and gets options on 12,158 shares - Stock Titan
Kiniksa (KNSA) director Malley exercises RSUs and receives new option grant - Stock Titan
Kiniksa (KNSA) director exercises RSUs and receives new option grant - Stock Titan
Kiniksa Pharmaceuticals (KNSA) director gains shares and new equity awards - Stock Titan
Kiniksa (KNSA) awards RSUs and options to Baker-affiliated board representatives - Stock Titan
Kiniksa (KNSA) Q1 2026 Earnings Transcript - The Globe and Mail
Kiniksa Pharmaceuticals International, plc Files Form 8-K Detailing Annual Meeting Results and Company Information - Minichart
Kiniksa Shareholders Reelect Directors and Approve Auditor Mandates - The Globe and Mail
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41 - GuruFocus
Kiniksa Pharmaceuticals (KNSA) Declines 4.84% as Stock Tests Key Support ZoneSupport Level Bounce - The Legal Advocate
Kiniksa (NASDAQ: KNSA) investors approve board, PwC auditor roles and pay - Stock Titan
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Kiniksa Pharmaceuticals Q1 2026 Earnings: EPS Surprises by 31.5% Despite Stock DeclineRevenue Breakdown Analysis - newsline.com
Kiniksa Pharmaceuticals Files 8-K Disclosing Waiver of Share Conversion Rights with Baker Brothers Life Sciences 9 - Minichart
Kiniksa Pharmaceuticals Caps Major Shareholder Voting Control Rights - TipRanks
Baker Bros sets 49.9% voting cap in Kiniksa (NASDAQ: KNSA) - Stock Titan
Kiniksa (NASDAQ: KNSA) sets 49.9% voting cap for Baker Bros. conversions - Stock Titan
Kiniksa Pharmaceuticals (KNSA) Holds Near Flat as Stock Consolidates Near Key LevelsBullish Pattern Stocks - The Legal Advocate
UBS Group AG Purchases 28,099 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Raises Revenue Guidance After Strong ARCALYST Growth - HarianBasis.co
Kiniksa Pharmaceuticals International (KNSA) price target increased by 10.10% to 63.53 - MSN
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
KNSA Q1 2026 Earnings: Strong EPS Beat Driven by Operational Efficiency and Product GrowthEarnings Power Value - thelegaladvocate.com
Vanguard Group Inc. Acquires 49,802 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month HighStill a Buy? - MarketBeat
How Kiniksa (KNSA) builds value over time (Institutional Demand) 2026-05-11Chaikin Flow - newsline.com
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Kiniksa Pharmaceuticals International : 2025 Annual Report - marketscreener.com
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Why Kiniksa Pharmaceuticals International stock raced nearly 24% higher today - MSN
FMR LLC amends filing showing 6,787,700.23 Kiniksa holdings (KNSA) - Stock Titan
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares - MarketBeat
Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):